hrp0095fc3.5 | Early Life and Multisystem Endocrinology | ESPE2022
Baillie George
, Kyurkchieva Elka
, Yan Sin Yuan
, Ahmed Faisal
, Rajapakse Navin
, Schoolmeesters Angela
, Richard Normand
, Erdman Paul
, Hecht David
, Hoskote Chourasia Aparajita
, Mercurio Frank
, Fung Leah
, Chan Kyle
, Stirling David
Background: Acrodysostosis Type 2 (ACRDYS2) is a rare autosomal dominant skeletal dysplasia associated with intellectual disability and gain-of-function mutations in the phosphodiesterase type 4D gene (PDE4D) which, in turn, leads to a paucity of intracellular cAMP due to increased PDE4D activity. This increased PDE4 activity may be due to a greater existence of a mutant monomeric form of PDE4D. To date, the clinical use of PDE4 inhibitors in ACRDYS2 has been ...